← Back to Search

Antiviral

STI-9199 for COVID-19

Phase 2

Waitlist Available

Research Sponsored by Sorrento Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through day 30

Awards & highlights

Study Summary

This trial is studying a possible COVID-19 treatment to see if it is safe and effective.

Eligible Conditions

COVID-19
Coronavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events (AEs) (safety)

Secondary outcome measures

Change in viral load

Participant perceived disease progression

Patient rated response

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: STI-9199Experimental Treatment1 Intervention

4 mg, 10 mg or 20 mg STI-9199 administered intranasally

Group II: PlaceboPlacebo Group1 Intervention

Placebo administered intranasally

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sorrento Therapeutics, Inc.Lead Sponsor

47 Previous Clinical Trials

1,964 Total Patients Enrolled

17 Trials studying COVID-19

939 Patients Enrolled for COVID-19

Mike Royal, MDStudy DirectorSorrento Therapeutics, Inc.

27 Previous Clinical Trials

1,495 Total Patients Enrolled

15 Trials studying COVID-19

833 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any more patients needed to participate in this clinical trial?

"The clinical trial in question, which can be found on clinicaltrials.gov, is not currently looking for patients. This particular study was originally posted on April 4th, 2022 and was last updated on August 15th of the same year. Although this specific trial isn't searching for volunteers at the moment, there are 1,129 other trials that are still recruiting participants."

Answered by AI

What have researchers found to be the dangers of STI-9199?

"While there is some data indicating that STI-9199 is safe, it only received a Phase 2 score of 2 because there is no efficacy data to support its use."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

2023. "Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05372783.